ClinicalTrials.gg
CompletedNCT01025817Updated Nov 11, 2015Results posted

Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients

A Phase 3 interventional study of Everolimus and tacrolimus and mycophenolate mofetil and tacrolimus in Kidney Transplant, sponsored by Novartis Pharmaceuticals. Completed at 50 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-11-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
613
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this phase 3b study is to compare the safety and efficacy of everolimus with low dose tacrolimus to mycophenolate mofetil with standard dose tacrolimus in kidney transplant recipients.

02

Conditions studied

  • Kidney Transplant

Keywords

  • Kidney transplant
  • renal transplant
  • immunosuppression
  • mycophenolate mofetil
  • tacrolimus
  • everolimus
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female renal recipients 18-70 years of age undergoing kidney transplantation, either primary or re-transplant;
  • Recipient of a cadaveric, deceased donor (including expanded criteria donor organs and deceased donor organs after cardiac death), living unrelated or non-HLA identical living related donor kidney;
  • Graft must be functional (producing greater than or equal to 100 ml of urine within 24 hours after transplantation) at time of randomization.

Exclusion criteria

Exclusion criteria:

  • Donor organ with a cold ischemic time > 30 hours;
  • Males or females who produce less than 100 ml of urine in the first 24 hours post-transplantation;
  • Males or females who are recipients of ABO incompatible transplants, or T cell, or B cell crossmatch positive transplant;
  • Males or females with severe total hypercholesterolemia or total hypertriglyceridemia (Patients on lipid lowering treatment with controlled hyperlipidemia are acceptable);
  • Males or females who have any surgical or any medical condition, such as severe diarrhea, active peptic ulcer disease, or uncontrolled diabetes mellitus, which in the opinion of the investigator, might alter the absorption, distribution, metabolism and/or excretion of study medication.

Other protocol related inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
613 participants (actual)

Study arms

  • Experimental
    Everolimus (EVR) & low dose of tacrolimus

    Everolimus (EVR) and tacrolimus treatment arm: Therapeutic drug monitoring of everolimus and tacrolimus was mandatory throughout the study. From Day 5 onwards, the everolimus 0.75 mg b.i.d. dose was increased if the trough level was \< 3 ng/mL, or reduced if the trough level was \> 8 ng/mL. Tacrolimus was initiated according to local practice. In this treatment arm, the tacrolimus dose was adjusted from Day 3 onwards, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From Month 2 until Month 6, the target tacrolimus trough level was 3 ng/mL to 6 ng/mL. After Month 6, the tacrolimus dose was adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL.

    Drug: Everolimus and tacrolimus

  • Active comparator
    Mycophenolate mofetil & standard dose tacrolimus

    Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.

    Drug: mycophenolate mofetil and tacrolimus

Interventions

  • DrugEverolimus and tacrolimus

    Drug pages: Everolimus · Tacrolimus

    Everolimus: * Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets * Dose: 1.5 mg per day * Frequency: 0.75 mg twice daily Tacrolimus: * Dose adjusted to maintain specific blood levels

  • Drugmycophenolate mofetil and tacrolimus

    Drug pages: Mycophenolic Acid · Tacrolimus

    Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels

    Also known as: Active Comparator Control)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Incidence of Composite Efficacy Failure

    Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\*, (2) graft loss\*\*, (3) participant death or(4) loss to follow-up. \*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \*\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis.

    Time frame: 12 Months

Secondary outcomes

  1. Estimated Glomerular Filtration Rate (eGFR)

    Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \[mL/min/1.73m˄2\] = 186.3\*(C˄-1.154)\*(A˄-0.203)\*G\*R. DEFINITIONS: C = serum concentration of creatinine \[mg/dL\]; A = age \[years\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1

    Time frame: 12 Months

  2. Number of Participants With Incidence of CMV (Viremia, Syndrome and Disease)

    Participants with incidence of CMV (viremia, syndrome and disease). CMV is cytomegalovirus.

    Time frame: 12 Months

  3. Number of Participants With Incidence Rates of BKV Viremia, BKV Viruria, or BKV Nephropathy

    Participants with Incidence of BKV (viremia, viruria, or nephropathy). BKV is Polyomavirus type BK.

    Time frame: 12 Months

  4. Number of Participants With Incidence of New Onset of Diabetes Mellitus

    Incidence of new onset diabetes mellitus defined as non-diabetic patients before transplantation, who are receiving glucose lowering treatment for more than 30 days post-transplant, or with a random plasma glucose ≥200 mg dL (11.1 mmol/L) with 2 fasting plasma glucose values ≥126 mg/dL (7 mmol/L)

    Time frame: 12 Months

  5. Number of Participants With Incidence of Proteinuria Events

    Number of participants with Incidence of proteinuria events indicating chronic kidney disease

    Time frame: Baseline and 12 Months

  6. Number of Participants With Incidence of Adverse Events, Serious Adverse Events, and Tacrolimus-associated Adverse Events

    Incidence of adverse events, serious adverse events, and tacrolimus-associated adverse events by System Organ Class

    Time frame: 12 Months

07

Results

Posted Jun 6, 2014
Limitations and caveats
HLA mismatches ≥3, everolimus group 261 vs MMF group 240

Participant flow

In total 738 participants were screened, and 613 were transplanted and randomized to treatment (n=309 to EVR+Low TAC dose and n=304 to MMF+Std TAC). EVR=Everolimus and low dose tacrolimus, and MMF=Mycophenolate mofetil and standard dose tacrolimus.

Completed Study Medication
Participant flow — Completed Study Medication
MilestoneEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Started309304
Completed204232
Not completed10572
Withdrew: Adverse event6639
Withdrew: Protocol deviation98
Withdrew: Withdrawal by subject89
Withdrew: Administrative problems75
Withdrew: Unsatisfactory therapeutic effect70
Withdrew: Abnormal test procedure40
Withdrew: Graft loss25
Withdrew: Death22
Withdrew: Abnormal lab values02
Withdrew: Subject no longer required study drug01
Withdrew: Lost to follow-up01
Completed Study
Participant flow — Completed Study
MilestoneEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Started309304
Completed293282
Not completed1622
Withdrew: Withdrawal by subject816
Withdrew: Death65
Withdrew: Missing20
Withdrew: Lost to follow-up01

Outcome measures

PrimaryNumber of Participants With Incidence of Composite Efficacy Failure

Efficacy failure rate used the composite endpoint of: (1) treated biopsy-proven acute rejection (BPAR)\*, (2) graft loss\*\*, (3) participant death or(4) loss to follow-up. \*A treated BPAR was defined as a biopsy graded IA, IB, IIA, IIB, or III and which was treated with anti-rejection therapy. \*\*Graft loss is defined as when the allograft was presumed lost on the day the participant started dialysis and was not able to subsequently be removed from dialysis.

Time frame:
12 Months
Reported as:
Number · Participants
Number of Participants With Incidence of Composite Efficacy Failure
ParticipantsEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Composite Endpoint7662
Treated Biopsy-proven Acute rejection (BPAR)5934
Graft Loss412
Death65
Loss to follow up917
SecondaryEstimated Glomerular Filtration Rate (eGFR)

Renal function was assessed by estimated Glomerular Filtration Rate (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula. MDRD formula: GFR \[mL/min/1.73m˄2\] = 186.3\*(C˄-1.154)\*(A˄-0.203)\*G\*R. DEFINITIONS: C = serum concentration of creatinine \[mg/dL\]; A = age \[years\]; G = 0.742 when gender is female, otherwise G = 1; R = 1.21 when race is black, otherwise R = 1

Time frame:
12 Months
Reported as:
Mean · mL/min/1.73m˄2
Estimated Glomerular Filtration Rate (eGFR)
mL/min/1.73m˄2Everolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Estimated Glomerular Filtration Rate (eGFR)63.14 ± 22.04263.06 ± 19.512
SecondaryNumber of Participants With Incidence of CMV (Viremia, Syndrome and Disease)

Participants with incidence of CMV (viremia, syndrome and disease). CMV is cytomegalovirus.

Time frame:
12 Months
Reported as:
Number · Participants
Number of Participants With Incidence of CMV (Viremia, Syndrome and Disease)
ParticipantsEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
CMV syndrome event913
Lab evidence of CMV Viremia710
CMV Disease28
SecondaryNumber of Participants With Incidence Rates of BKV Viremia, BKV Viruria, or BKV Nephropathy

Participants with Incidence of BKV (viremia, viruria, or nephropathy). BKV is Polyomavirus type BK.

Time frame:
12 Months
Reported as:
Number · Participants
Number of Participants With Incidence Rates of BKV Viremia, BKV Viruria, or BKV Nephropathy
ParticipantsEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Lab evidence of BKV Viremia1927
Lab evidence of BKV Viruria1915
BKV Disease (Nephropathy)55
SecondaryNumber of Participants With Incidence of New Onset of Diabetes Mellitus

Incidence of new onset diabetes mellitus defined as non-diabetic patients before transplantation, who are receiving glucose lowering treatment for more than 30 days post-transplant, or with a random plasma glucose ≥200 mg dL (11.1 mmol/L) with 2 fasting plasma glucose values ≥126 mg/dL (7 mmol/L)

Time frame:
12 Months
Reported as:
Number · Participants
Number of Participants With Incidence of New Onset of Diabetes Mellitus
ParticipantsEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Any New Onset Diabetes2522
randomGlucose≥200mg/dL w/2 fastingGlucose≥126mg/dL1512
Concomitant Diabetes medicine for 30 days or more1314
SecondaryNumber of Participants With Incidence of Proteinuria Events

Number of participants with Incidence of proteinuria events indicating chronic kidney disease

Time frame:
Baseline and 12 Months
Reported as:
Number · Participants
Number of Participants With Incidence of Proteinuria Events
ParticipantsEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Baseline: Proteinuria (>=300 mg/g)243250
Month 12, Day 316-450: Proteinuria (>=300 mg/g)3635
SecondaryNumber of Participants With Incidence of Adverse Events, Serious Adverse Events, and Tacrolimus-associated Adverse Events

Incidence of adverse events, serious adverse events, and tacrolimus-associated adverse events by System Organ Class

Time frame:
12 Months
Reported as:
Number · Participants
Number of Participants With Incidence of Adverse Events, Serious Adverse Events, and Tacrolimus-associated Adverse Events
ParticipantsEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Any system organ class303302
Metabolism and nutrition disorders266263
Gastrointestinal disorders233247
Injury, poisoning and procedural complications223202
General disorders &administration site conditions199177
Infections and infestations184196
Investigations150143
Renal and urinary disorders141160
Vascular disorders131121
Blood and lymphatic system disorders130163
Nervous system disorders125150
Respiratory, thoracic and mediastinal disorders122134
Musculoskeletal and connective tissue disorders110114
Skin and subcutaneous tissue disorders109108
Psychiatric disorders96106
Reproductive system and breast disorders5640
Cardiac disorders5147
Eye disorders2636
Immune system disorders1311
Endocrine disorders128
Neoplasms benign,malignant,other incl cysts/polyps1015
Ear and labyrinth disorders711
Hepatobiliary disorders63
Surgical and medical procedures20
Congenital, familial and genetic disorders06
Social circumstances01

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Everolimus and Low Dose Tacrolimus—154/306 (50.3%)302/306 (98.7%)
Mycophenolate Mofetil and Standard Dose Tacrolimus—142/304 (46.7%)299/304 (98.4%)
Most frequent serious events
Showing 10 of 302
Most frequent serious events
EventEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
Urinary tract infectionInfections and infestations22/30624/304
Renal failure acuteRenal and urinary disorders7/30616/304
Blood creatinine increasedInvestigations10/30614/304
PyrexiaGeneral disorders13/30611/304
PneumoniaInfections and infestations13/3067/304
Graft dysfunctionInjury, poisoning and procedural complications9/3068/304
DiarrhoeaGastrointestinal disorders7/3068/304
VomitingGastrointestinal disorders8/3067/304
UrosepsisInfections and infestations5/3067/304
Diabetes mellitusMetabolism and nutrition disorders2/3067/304
Most frequent other events
Showing 10 of 69
Most frequent other events
EventEverolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose Tacrolimus
NauseaGastrointestinal disorders111/306134/304
HypomagnesaemiaMetabolism and nutrition disorders102/306124/304
DiarrhoeaGastrointestinal disorders74/306122/304
ConstipationGastrointestinal disorders119/306120/304
Oedema peripheralGeneral disorders113/30688/304
HypophosphataemiaMetabolism and nutrition disorders108/30694/304
Procedural painInjury, poisoning and procedural complications93/30694/304
HyperkalaemiaMetabolism and nutrition disorders93/30681/304
TremorNervous system disorders51/30686/304
AnaemiaBlood and lymphatic system disorders83/30667/304

Baseline characteristics

Full Analysis Set (FAS) consisted of all participants randomized after transplantation. \*The discrepancy with the Ns is that there are 613 participants overall and 610 in the safety population.

Age, Continuous
Age, Continuous(Years)Everolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose TacrolimusTotal
Mean50.00 ± 13.3448.4 ± 12.9149.2 ± 13.14
Sex: Female, Male
Sex: Female, Male(Participants)Everolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose TacrolimusTotal
Female101102203
Male205202407
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Everolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose TacrolimusTotal
American Indian or Alaska Native314
Asian171128
Native Hawaiian or Other Pacific Islander314
Black or African American7074144
Caucasian196201397
Other171633
BMI
BMI(kg/m˄2)Everolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose TacrolimusTotal
Mean27.7 ± 5.5528.3 ± 5.1328.0 ± 5.35
Diabetic status at randomization
Diabetic status at randomization(Participants)Everolimus and Low Dose TacrolimusMycophenolate Mofetil and Standard Dose TacrolimusTotal
Yes11195206
No195209404
08

Study locations

50 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35233, United States
  • Novartis Investigative Site
    Tucson, Arizona 85742-5022, United States
  • Novartis Investigative Site
    Los Angeles, California 90033, United States
  • Novartis Investigative Site
    Los Angeles, California 90048, United States
  • Novartis Investigative Site
    Los Angeles, California 90095, United States
  • Novartis Investigative Site
    Orange, California 92868, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    San Diego, California 92103, United States
  • Novartis Investigative Site
    San Diego, California 92123, United States
  • Novartis Investigative Site
    San Francisco, California 94115, United States
  • Novartis Investigative Site
    San Francisco, California 94143-0780, United States
  • Novartis Investigative Site
    Aurora, Colorado 80045, United States
  • Novartis Investigative Site
    Miami, Florida 33136, United States
  • Novartis Investigative Site
    Orlando, Florida 32804, United States
  • Novartis Investigative Site
    Tampa, Florida 33606, United States
  • Novartis Investigative Site
    Chicago, Illinois 60612, United States
  • Novartis Investigative Site
    Chicago, Illinois 60637, United States
  • Novartis Investigative Site
    Baltimore, Maryland 21201, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02111, United States
  • Novartis Investigative Site
    Worcester, Massachusetts 01655, United States
  • Novartis Investigative Site
    Ann Arbor, Michigan 48109-0331, United States
  • Novartis Investigative Site
    Detroit, Michigan 48202-2689, United States
  • Novartis Investigative Site
    Detroit, Michigan 48236, United States
  • Novartis Investigative Site
    Royal Oak, Michigan 48073, United States
  • Novartis Investigative Site
    Minneapolis, Minnesota 55455, United States
  • Novartis Investigative Site
    St. Louis, Missouri 63110, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68198-3285, United States
  • Novartis Investigative Site
    Livingston, New Jersey 07039, United States
  • Novartis Investigative Site
    Buffalo, New York 14215, United States
  • Novartis Investigative Site
    New York, New York 10032, United States
  • Novartis Investigative Site
    Durham, North Carolina 27710, United States
  • Novartis Investigative Site
    Greenville, North Carolina 27834, United States
  • Novartis Investigative Site
    Portland, Oregon 97239, United States
  • Novartis Investigative Site
    Harrisburg, Pennsylvania 17105-8700, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29425, United States
  • Novartis Investigative Site
    Nashville, Tennessee 37212-3139, United States
  • Novartis Investigative Site
    Dallas, Texas 75246, United States
  • Novartis Investigative Site
    Fort Worth, Texas 76104, United States
  • Novartis Investigative Site
    Galveston, Texas 77555-0144, United States
  • Novartis Investigative Site
    Houston, Texas 77030, United States
  • Novartis Investigative Site
    Lubbock, Texas 79430, United States
  • Novartis Investigative Site
    Salt Lake City, Utah 84132, United States
  • Novartis Investigative Site
    Burlington, Vermont 05401, United States
  • Novartis Investigative Site
    Charlottesville, Virginia 22908, United States
  • Novartis Investigative Site
    Norfolk, Virginia 23507, United States
  • Novartis Investigative Site
    Richmond, Virginia 23298, United States
  • Novartis Investigative Site
    Seattle, Washington 98195, United States
  • Novartis Investigative Site
    Spokane, Washington 99204, United States
  • Novartis Investigative Site
    Montreal, Quebec H1T 2M4, Canada
  • Novartis Investigative Site
    Montreal, Quebec H2L 4M1, Canada
09

References and documents

Publications

  • Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, Shaffer D. Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus. Am J Transplant. 2017 Sep;17(9):2363-2371. doi: 10.1111/ajt.14215. Epub 2017 Mar 4. PubMed 28141897 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2009
First posted
Dec 4, 2009
Start
Jan 2010
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Jun 6, 2014
Last update
Nov 11, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 11, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01025817
Responsible party
Sponsor
First posted
Dec 4, 2009
Start date
Jan 2010
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Jun 6, 2014
Last update
Nov 11, 2015

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Everolimus · Tacrolimus

Start the discussion